Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway
Ibrutinib, a bruton tyrosine kinase (BTK) inhibitor which suppresses B-cell receptor signaling, has remarkably improved the outcome of patients with mantle cell lymphoma (MCL). However, approximately 33% of MCL patients have primary Ibrutinib resistance, and acquired Ibrutinib resistance is nearly u...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
PeerJ Inc.
2021-12-01
|
| Schriftenreihe: | PeerJ |
| Schlagworte: | |
| Online-Zugang: | https://peerj.com/articles/12571.pdf |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|